Last reviewed · How we verify
Provenge
At a glance
| Generic name | Provenge |
|---|---|
| Sponsor | GenesisCare USA |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
- Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer (PHASE2)
- Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer (PHASE1)
- 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PHASE1)
- Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC (PHASE2)
- Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T (PHASE2)
- Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (PHASE3)
- Tonsil Surgery in Recurrent or Chronic Tonsillitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Provenge CI brief — competitive landscape report
- Provenge updates RSS · CI watch RSS
- GenesisCare USA portfolio CI